GeneTex
United States (US)

VEGFB recombinant protein

Cat No. GTX65278

Application ELISA, Functional Assay, Apuri, Blocking
Reactivity Human
Species Human
APPLICATION

Application Note

Per researcher’s feedback, the protein is biologically active as determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) in the presence of human VEGF165. The expected ED50 for this effect is 0.5-5.0 ug/ml.

Calculated MW

19.63 kDa. ( Note )
PROPERTIES

Form

Lyophilized powder

Storage

Reconstitute in 0.1% acetic acid to a concentration of 0.1-1.0 mg/ml. The solution should be stored at -70ºC.

Antigen Species

Human

Expression System

E. coli

Purification


Purity was assessed by SDS-PAGE (≥98%) and by HPLC.

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

Vascular Endothelial Growth Factor-B, Vascular Endothelial Growth FactorB, VEGFB, VEGFL, VRF

Background

VEGF-B, a member of the VEGF family, is a potent growth and angiogenic cytokine. It promotes DNA synthesis in endothelial cells, regulates angiogenesis and Vascular permeability, and inhibits apoptosis in certain smooth muscle cells and neurons. VEGF-B is expressed in all tissues except the liver. It forms cell surfaced-associated disulfide linked homodimers and can form heterodimers with VEGF-A. There are two known isoforms, formed by alternative splicing, which have been designated VEGF-B167 and VEGF-B186. Both forms have identical amino-terminal sequences encoding a “cysteine knot” like structural motif, but differ in their carboxyl-terminal domains. Both VEGF-B isoforms signal only through the VEGFR1 receptor. Recombinant human VEGF-B is a 38.0 kDa disulfide-linked homodimeric protein consisting of two 167 amino acid polypeptide chains.

Research Area